Health ❯ Healthcare ❯ Patient Safety

Adverse Events

Device Malfunction Medical Interventions Self-Administration Risks Major Bleeding Device Malfunctions Injury Reporting Monitoring Hematologic Toxicity Clinical Investigations Monitoring and Investigation

3 ARTICLES

2w ago

Novartis Pauses CAR‑T Autoimmune Trials After Three Deaths

The company’s review with regulators and independent safety boards could alter efforts to use CD19‑targeting CAR‑T therapy for noncancer immune diseases.

9 ARTICLES

3w ago

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

4 ARTICLES

7mo ago

FDA Rejects Regenxbio’s Hunter Syndrome Gene Therapy Application

9 ARTICLES

7mo ago

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

6 ARTICLES

9mo ago

Recalls Expand for Abbott FreeStyle Libre 3 Sensors Over False Low Readings

14 ARTICLES

9mo ago

FDA Issues Early Alert on Certain FreeStyle Libre 3 Sensors After False Low Readings Linked to Harm

3 ARTICLES

10mo ago

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

4 ARTICLES

10mo ago

FDA Issues Safety Alert on RF Microneedling Injuries

4 ARTICLES

this yr.

Low-Dose Transplant Drug Preserves Beta Cells in Young People With Type 1 Diabetes, Phase 2 Trial Finds

3 ARTICLES

this yr.

World Patient Safety Day 2025 Centers on Safer Care for Newborns and Children

3 ARTICLES

last yr.

Capsida Halts STXBP1 Gene Therapy Trial After First Pediatric Participant Dies

5 ARTICLES

last yr.

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

10 ARTICLES

last yr.

ESC Trials Recast Antiplatelet Strategies After PCI and CABG

3 ARTICLES

last yr.

Tandem Diabetes Announces Urgent Medical Device Correction for t:slim X2 Pumps

3 ARTICLES

last yr.

Safety and Cost Concerns Fuel Push to Restrict Spinal Cord Stimulators in Australia

9 ARTICLES

last yr.

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

8 ARTICLES

last yr.

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure

Adverse Events

Novartis Pauses CAR‑T Autoimmune Trials After Three Deaths

Vitruvias Recalls Lot of Thyroid Tablets Over 'Superpotent' Test Results

Audit Slams French Hospital Safety Gaps, Calls for Tougher Reporting

Roche Starts Placebo-Controlled Phase 3 Trial of Elevidys to Pursue EU Approval

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

FDA Rejects Regenxbio’s Hunter Syndrome Gene Therapy Application

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Recalls Expand for Abbott FreeStyle Libre 3 Sensors Over False Low Readings

FDA Issues Early Alert on Certain FreeStyle Libre 3 Sensors After False Low Readings Linked to Harm

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

Never miss stories about

Adverse Events

FDA Issues Safety Alert on RF Microneedling Injuries

Low-Dose Transplant Drug Preserves Beta Cells in Young People With Type 1 Diabetes, Phase 2 Trial Finds

World Patient Safety Day 2025 Centers on Safer Care for Newborns and Children

Capsida Halts STXBP1 Gene Therapy Trial After First Pediatric Participant Dies

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

ESC Trials Recast Antiplatelet Strategies After PCI and CABG

Tandem Diabetes Announces Urgent Medical Device Correction for t:slim X2 Pumps

Safety and Cost Concerns Fuel Push to Restrict Spinal Cord Stimulators in Australia

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure

Never miss stories about

Adverse Events